We discovered that tumor growth in the Arih1-WT-OE group was significantly decreased compared with wild-type control, and treating with anti-PD-L1 led to a further decrease in tumor burden and achieved complete regression (Fig. 2a–c). Here, ARIH1 is linked to neoplasm.